Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02164695
Other study ID # CR314003
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 31, 2015
Est. completion date January 31, 2018

Study information

Verified date November 2021
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate whether remote ischemic per-conditioning (RIPC) can reduce infarct size in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PPCI) within 12 hours of symptoms onset. - Control group: PPCI only - Study group: PPCI + RIPC Primary endpoint: Infarct size measured by contrast-enhanced cardiac magnetic resonance (CMR) at 6 months after the index procedure


Description:

ST-elevation myocardial infarction (STEMI) is a leading cause of mortality and morbidity. Early myocardial reperfusion with either of thrombolytic therapy or primary percutaneous coronary intervention (PPCI) is the most effective strategy for reducing the size of a myocardial infarct and improving the clinical outcome. Although this process can restore blood flow to the ischemic myocardium, it can induce injury. This phenomenon termed myocardial reperfusion injury can paradoxically reduce the beneficial effects of myocardial reperfusion. The pre-clinical study in animal models of acute myocardial infarction suggests that lethal reperfusion injury accounts for up to 50% of the final size of a myocardial infarct. Remote ischemic conditioning uses brief ischemia and reperfusion of a distant organ to protect the myocardium. In animal study, remote ischemic postconditioning seems to be more effective than local postconditioning in experimental myocardial infarction.Bøtker et al. has reported remote ischemic preconditioning before hospital admission increase myocardial salvage in patients with acute myocardial infarction. The objective of this study is to evaluate whether remote ischemic per-conditioning (RIPC) can reduce late infarct size in patients with STEMI treated with PPCI within 12 hours of symptoms onset. To test this hypothesis, we will randomize patients into PPCI + RIPC or PPCI alone. We will evaluate marker of reperfusion injury using contrast cardiac magnetic resonance image.


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date January 31, 2018
Est. primary completion date July 31, 2017
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Age >19 years - Presenting within 12 hours of symptom onset - >20 min of chest pain - ST-elevation myocardial infarction defined as ST-segment elevation (>0.1 mV) in at least 2 contiguous precordial leads Exclusion Criteria: - Previous myocardial infarction - Presence of chronic total occlusion - Evidence of retrograde filling by collaterals at coronary angiography (Rentrop 2 or 3 collateral flow) - Severe multi-vessel coronary artery disease to require further interventions before follow-up CMR - Cardiac arrest before randomization - Arrhythmias requiring external electric shock before randomization - Unwillingness to participate - External electric shock for cardioversion within first 3 days - Cardiac surgery within first 3 days

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PPCI plus RIPC
All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
PPCI only
All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.

Locations

Country Name City State
Korea, Republic of Wonju Severance Christian Hospital Wonju Gangwon

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Infarct size measured by contrast-enhanced cardiac magnetic resonance Infarct size will be assessed on late-contrast images (˜10 min after gadolinium administration) by manually tracing the hyperintense area in each short-axis slice. 6 months after index procedure
Secondary Enzymatic Infarct Size Enzymatic infarct size will be assessed by the area under the curve of creatine kinase-myocardial band (CK-MB) and troponin I (TnI) release. Blood samples will be collected before PCI and every day after index PPCI. Area under the curve of CK-MB and troponin I release will be expressed in arbitrary units and calculated with the trapezoidal method. 1 to 5 days after index procedure
Secondary Resolution of ST-segment deviation ST-segment deviation score will be measured in 12-lead electrocardiograms, calculated as the sum (in millimeters) of ST-segment deviation (elevation or depression) at 80 ms after the J-point in all 12 leads. ST-segment deviation score will be measured at presentation and 30 min after PCI, by 2 physicians blinded as to the patients' data, and the mean value of the 2 assessments will be used. ST-segment resolution will be calculated as a percentage: ratio of the reduction in ST-segment deviation score from presentation to half an hour after PCI over the ST-segment deviation score at presentation × 100% (i.e., [(ST-segment deviation at presentation - ST-segment deviation post-PCI)/ST-segment deviation at presentation] × 100%). Full ST-segment resolution will be defined as 80% or more reduction of ST-segment deviation score. 1 to 5 days after index procedure
Secondary Acute kidney injury Acute kidney injury will be defined as an absolute increase in serum creatinine of =0.5 mg/dl or a relative increase of =25% compared with baseline within 96 h after PCI (the maximal measured concentration of serum creatinine during these 96 h will be used). Relative reduction in estimated glomerular filtration rate (eGFR), calculated with the Modification of Diet in Renal Disease formula, within 96 h after PCI will be assessed. 1 to 3 days after index procedure
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Recruiting NCT02894138 - Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study Phase 3
Completed NCT02641262 - Henan STEMI Registry
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Recruiting NCT01738100 - Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention Phase 2
Completed NCT05895123 - Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients Phase 2
Completed NCT03671603 - Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
Recruiting NCT02606435 - Thrombus Aspiration in Patients With STEMI Phase 4
Completed NCT01203982 - Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT) Phase 4
Active, not recruiting NCT03338309 - INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry
Recruiting NCT02445885 - Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction N/A
Not yet recruiting NCT04984915 - The Usefulness of CaIMR in Patients With STEMI
Active, not recruiting NCT03371784 - The Effect of Glucocorticoid Therapy on Left Ventricular Remodelling in Acute Myocardial Infarction (RECONSIDER) Phase 2/Phase 3
Completed NCT03389503 - Comparison of Left and Right Transradial Approach for CAG and PCI N/A
Completed NCT02311231 - Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART Phase 4
Completed NCT02324348 - Efficacy and Safety Study of Deferred Stenting in Patients With STEMI N/A
Completed NCT01385631 - Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction. Phase 4
Completed NCT03690713 - International Collaboration of Comprehensive Physiologic Assessment
Enrolling by invitation NCT02670005 - Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction N/A
Active, not recruiting NCT02070471 - Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients Phase 2